Ibio Company Leadership
| IBIO Stock | USD 2.83 0.01 0.35% |
Ibio employs about 16 people. The company is managed by 13 executives with a total tenure of roughly 17 years, averaging almost 1.0 years of service per executive, having 1.23 employees per reported executive. Analysis of Ibio's management performance can provide insight into the firm performance.
| Robert Kay Chairman Executive Chairman and CEO |
Ibio |
Ibio's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Ibio's future performance. Based on our forecasts, it is anticipated that Ibio will maintain a workforce of about 16 employees by February 2025.Ibio Management Team Effectiveness
The company has return on total asset (ROA) of (0.2973) % which means that it has lost $0.2973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8415) %, meaning that it created substantial loss on money invested by shareholders. Ibio's management efficiency ratios could be used to measure how well Ibio manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of January 2025, Return On Tangible Assets is likely to drop to -1.01. In addition to that, Return On Capital Employed is likely to drop to -0.63. At this time, Ibio's Total Assets are very stable compared to the past year. As of the 18th of January 2025, Non Current Assets Total is likely to grow to about 17.9 M, while Other Current Assets are likely to drop about 818.3 K.As of the 18th of January 2025, Common Stock Shares Outstanding is likely to grow to about 4.6 M, though Net Loss is likely to grow to (55.6 M).
Ibio Workforce Comparison
Ibio Inc is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,578. Ibio claims roughly 16.0 in number of employees contributing just under 2% to equities under Health Care industry.
Ibio Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ibio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ibio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Ibio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-06-01 | 2.0 | 4 | 2 | 383,100 | 84,000 |
| 2023-09-01 | 0.4 | 2 | 5 | 180,000 | 59,546 |
| 2023-06-01 | 0.1429 | 1 | 7 | 75,833 | 88,581 |
| 2023-03-01 | 1.0 | 3 | 3 | 217,500 | 9,189 |
| 2022-09-01 | 1.3333 | 4 | 3 | 5,100,000 | 13,600 |
| 2021-12-01 | 8.0 | 8 | 1 | 872,000 | 37,243 |
| 2020-09-01 | 0.1429 | 1 | 7 | 28,925,000 | 28,758,826 |
| 2020-06-01 | 1.0 | 6 | 6 | 1,910,642 | 271,284 |
| 2020-03-01 | 3.0 | 6 | 2 | 1,353,044 | 121,976 |
| 2019-03-01 | 0.1733 | 13 | 75 | 113,252 | 1,358,001 |
| 2017-03-01 | 1.0 | 1 | 1 | 1.00 | 150,000 |
| 2016-03-01 | 2.0 | 2 | 1 | 5,284,000 | 1,784,000 |
| 2014-09-01 | 3.0 | 9 | 3 | 1,610,000 | 138,710 |
| 2014-03-01 | 0.0909 | 1 | 11 | 100,000 | 434,342 |
| 2013-12-01 | 0.5 | 2 | 4 | 15,000,000 | 15,030,633 |
| 2013-09-01 | 0.6 | 9 | 15 | 2,692,679 | 616,419 |
| 2012-03-01 | 0.0968 | 3 | 31 | 235,000 | 359,890 |
| 2010-12-01 | 3.0 | 3 | 1 | 1,500,000 | 60,000 |
| 2008-09-01 | 1.0 | 6 | 6 | 469,150 | 0.00 |
Ibio Notable Stakeholders
An Ibio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ibio often face trade-offs trying to please all of them. Ibio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ibio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Robert Kay | Executive Chairman and CEO | Profile | |
| Lisa Middlebrook | Chief Officer | Profile | |
| Stephen Kilmer | Investor Officer | Profile | |
| Marc JD | General Counsel | Profile | |
| Melissa Berquist | VP Health | Profile | |
| Robert Lutz | Chief Officer | Profile | |
| Dr DVM | Chief Officer | Profile | |
| Mike Jenkins | VP Operations | Profile | |
| Thomas III | Pres CEO | Profile | |
| Randy Maddux | Strategic Advisor | Profile | |
| Kristi Sarno | Senior Development | Profile | |
| Felipe Duran | Chief Officer | Profile | |
| Nick DeLong | VP Devel | Profile |
About Ibio Management Performance
The success or failure of an entity such as Ibio Inc often depends on how effective the management is. Ibio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ibio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ibio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.96) | (1.01) | |
| Return On Capital Employed | (0.60) | (0.63) | |
| Return On Assets | (0.78) | (0.82) | |
| Return On Equity | (1.05) | (1.10) |
Ibio Workforce Analysis
Traditionally, organizations such as Ibio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ibio within its industry.Ibio Manpower Efficiency
Return on Ibio Manpower
| Revenue Per Employee | 14.1K | |
| Revenue Per Executive | 17.3K | |
| Net Loss Per Employee | 1.6M | |
| Net Loss Per Executive | 1.9M | |
| Working Capital Per Employee | 739.5K | |
| Working Capital Per Executive | 910.2K |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ibio Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ibio. If investors know Ibio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ibio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.03) | Revenue Per Share | Quarterly Revenue Growth (0.88) | Return On Assets | Return On Equity |
The market value of Ibio Inc is measured differently than its book value, which is the value of Ibio that is recorded on the company's balance sheet. Investors also form their own opinion of Ibio's value that differs from its market value or its book value, called intrinsic value, which is Ibio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ibio's market value can be influenced by many factors that don't directly affect Ibio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ibio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ibio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ibio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.